F

or the first time, the World Health Organization has sanctioned use of a generic hepatitis C medicine by the United Nations and other agencies in hopes of widening access to a needed treatment.

Specifically, the WHO wants to encourage greater use of lower-cost versions of Sovaldi in dozens of countries where public health advocates say availability has been impeded by bureaucratic delays to an access plan hatched three years ago by Gilead Sciences, which sells the brand-name drug.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Stylish new page look, I see? Meanwhile, that’s quite a price adjustment – $3/USD per pill, down from $1,000 USD. And Mylan will still make money? Or will they be relying on the EpiPen to make up the difference?

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.